MygoGenesis LLC
Research and commercialization organization developing a cell‑biology platform that converts somatic cells to totipotent cells and directs their differentiation for therapeutic and testing applications. The organization describes capabilities for scalable in vitro production of amebocytes for endotoxin (LAL) testing, laboratory production of blood cells, autologous cell banking, and platform licensing for medical and environmental testing use cases.
Industries
N/A
Products
Amebocyte production platform for endotoxin testing
An in vitro platform to expand and differentiate amebocyte precursors to produce bio‑identical amebocytes for Limulus amebocyte lysate (LAL) production used in endotoxin testing.
Laboratory production of Type O negative blood (development project)
In‑laboratory approaches to produce Type O negative erythroid cells with the goal of addressing blood supply shortages.
Totipotent cell production process for cell therapeutics
A platform process to convert patient somatic cells into totipotent cells, intended as input material for diverse regenerative and therapeutic applications.
Amebocyte production platform for endotoxin testing
An in vitro platform to expand and differentiate amebocyte precursors to produce bio‑identical amebocytes for Limulus amebocyte lysate (LAL) production used in endotoxin testing.
Laboratory production of Type O negative blood (development project)
In‑laboratory approaches to produce Type O negative erythroid cells with the goal of addressing blood supply shortages.
Totipotent cell production process for cell therapeutics
A platform process to convert patient somatic cells into totipotent cells, intended as input material for diverse regenerative and therapeutic applications.
Services
Platform partnership and licensing
Engagements to partner or license the cell‑production platform for research, testing, or commercial use.
Autologous cell banking
Storage service for patient‑derived totipotent cells for future therapeutic or diagnostic applications.
Platform partnership and licensing
Engagements to partner or license the cell‑production platform for research, testing, or commercial use.
Autologous cell banking
Storage service for patient‑derived totipotent cells for future therapeutic or diagnostic applications.
Expertise Areas
- Cellular reprogramming and totipotent cell production
- Directed differentiation for regenerative medicine
- Bioprocessing and scalable cell culture
- Endotoxin testing and assay validation
Key Technologies
- Cellular reprogramming
- Epigenetic resetting
- Directed differentiation
- Scalable cell culture / bioprocessing